Key Highlights

  • Evogene announced it will release third-quarter 2026 results on Thursday, November 19, 2026, with a management call the same day, and a preview page describes the report as before the open.
  • Published coverage, from a single preview page, shows a consensus loss of USD 0.19 per share on Revenue of about USD 370,000, matching the loss figure on the Earnings calendar.
  • Second-quarter revenue was USD 347,000 against USD 534,000 and the net loss was USD 1.8 million, or USD 0.14 a share, versus USD 4.7 million, or USD 0.62, a year earlier.
  • Cash was USD 9.3 million at June 30, 2026, and management guided 2026 cash usage of USD 8.5 million to USD 9.5 million, against about USD 14.4 million in 2025.

Company-Announced Date and a Single-Source Consensus

Evogene (NASDAQ:EVGN), listed on Nasdaq and the Tel Aviv exchange, uses generative AI to design small molecules for pharmaceutical and agricultural uses through its ChemPass AI platform. The company announced a third-quarter release for November 19, 2026, with a call hosted the same day. The consensus is a loss of USD 0.19 per share on revenue of about USD 370,000, up roughly 19% from a very small base, according to one preview page. Estimates for micro-caps like this are thin, so a single analyst can set the whole figure, and small swings in Warrant Revaluation can move the loss per share more than operations do. Evogene reports in US dollars.

Second Quarter Loss Narrowed on Warrant Revaluation

Evogene (NASDAQ:EVGN) last reported second-quarter and first-half results in August 2026. Revenue was USD 347,000 against USD 534,000 and the net loss narrowed to USD 1.8 million from USD 4.7 million, helped by about USD 972,000 of financing income, mostly warrant revaluation. Loss per share was USD 0.14 in the release, while the preview page showed USD 0.13, a small conflict resolved in favour of the release. For the first half, revenue was USD 681,000 versus USD 2.9 million. No consensus for the second quarter was found, so a beat or miss is not stated, and the share reaction was not verified.

Cash Burn, Collaboration Count and Bid-Price Compliance

Three metrics decide the read. Cash usage is first: cash fell from about USD 13.0 million at year-end to USD 9.3 million at June 30, a drop of about USD 3.7 million (calculated), and management guided full-year usage of USD 8.5 million to USD 9.5 million. Second is the collaboration count, which stood at six active drug discovery partnerships, four added in 2026, with two programs through the Hit Identification stage. Third is listing status: a company headline on September 30 said Nasdaq granted another 180 days to regain the minimum bid price. The preview page also cited about USD 2.4 million of at-the-market share sales and a terminated herbicide program, both single-source.

Where Things Stand

Evogene (NASDAQ:EVGN) has some runway, but not much. Cash of USD 9.3 million at mid-year against guided 2026 usage of USD 8.5 million to USD 9.5 million, plus at-the-market sales reported by one preview, suggests funding and dilution remain central to the story. A loss near the USD 0.19 estimate would not by itself settle that, so the reaction will likely turn on cash, new collaborations and the Nasdaq compliance path. The November 19 call is the next catalyst. A change in the collaboration count or new partner payments would also matter for revenue.